Another meta-analysis of eleven randomized-controlled trials (RCTs) evaluating the utilization of GLP-1 RAs for the management of NAFLD and NASH reached a conclusion that, in comparison with placebo or reference therapy, the use of GLP-1 RAs for a median of 26 weeks was correlated with notable reductions in the absolute percentage of liver fat content and serum liver enzyme levels, as well as with considerable histological resolution of NASH without the worsening of liver fibrosis [47]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.